During the corresponding time, Neuronetics Inc recorded a revenue increase by 10.25 % year on year, sequentially revenue grew by 21.88 %. While revenue at the Neuronetics Inc 's corporate clients
Neuronetics Inc's Comment on Sales, Marketing and Customers
The company operates Greenbrook treatment centers across the United States, providing NeuroStar Advanced Therapy and SPRAVATO® for adults with treatment-resistant depression and major depressive disorder (MDD) accompanied by acute suicidal ideation or behavior. Greenbrook, a wholly owned subsidiary, is a provider of mental healthcare services and a market leader in transcranial magnetic stimulation (TMS) therapy. As of December 31, 2025, the company has treated approximately 237,574 patients globally with over 8.5 million treatment sessions. The primary market served includes adults with MDD, a mood disorder with significant prevalence and economic impact worldwide. In the U.S., about 21 million individuals aged 22 to 70 experience MDD annually, with approximately 13.9 million receiving psychiatric treatment. Among these, around 6.4 million have not achieved remission following prior antidepressant therapy, and approximately 3.8 million have commercial insurance or federal healthcare coverage for NeuroStar Advanced Therapy. The estimated annual addressable market for treatment sessions in the U.S. is approximately $8.9 billion. Initial treatments typically involve antidepressant medications prescribed by primary care physicians, which have demonstrated limitations in effectiveness and side effects, as evidenced by the STAR*D Study.
NeuroStar Advanced Therapy: Revolutionizing Adolescent Depression Treatment AccessibilityNeuroStar Advanced Therapy, a groundbreaking treatment for depression utilizing transcranial magnetic stimulation (TMS), has recently received FDA clearance as a first-line add-on treatment for adolescents aged 15 and older. This clearance marks a significant milestone in the field of mental health, as NeuroStar becomes the first and only TMS therapy approved for this age group.Depression affects millions of adolescents worldwide, and finding effective treatment options can be challenging. While medication and therapy play an essential role in managing depression, not all patients respond adequately to these intervention...
Neuronetics, a leading medical technology company, has recently introduced the latest iteration of its TrakStar Patient Data Management System. This innovative system is poised to revolutionize the workflow efficiencies for NeuroStar Transcranial Magnetic Stimulation (TMS) providers, ensuring improved patient care and outcomes. By interpreting the articles Neuronetics Launches Latest Evolution in its TrakStar Patient Data Management System and Advancements provide workflow efficiencies for NeuroStar TMS providers, we can delve into the facts surrounding this significant development.Neuronetics has taken a significant step forward by releasing the most recent version of its TrakStar Patient Data Management Sy...
The landscape of mental health treatment is changing at an unprecedented pace, and at the heart of this transformation is a big change from Lucet Health, which is set to massively improve accessibility to Transcranial Magnetic Stimulation (TMS), a pioneering neurological therapy. Lucet Health, a prominent health insurance company, has updated its policy and changed its criteria, which dramatically reduces the requirements for treatment accessibility. This new development, in particular, impacts the reach and effectiveness of the NeuroStar TMS therapy, which uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression.NeuroStar TMS is among the frontline options the medical com...
Neuronetics Inc’s Comment on Sales, Marketing and Customers
The company operates Greenbrook treatment centers across the United States, providing NeuroStar Advanced Therapy and SPRAVATO® for adults with treatment-resistant depression and major depressive disorder (MDD) accompanied by acute suicidal ideation or behavior. Greenbrook, a wholly owned subsidiary, is a provider of mental healthcare services and a market leader in transcranial magnetic stimulation (TMS) therapy. As of December 31, 2025, the company has treated approximately 237,574 patients globally with over 8.5 million treatment sessions. The primary market served includes adults with MDD, a mood disorder with significant prevalence and economic impact worldwide. In the U.S., about 21 million individuals aged 22 to 70 experience MDD annually, with approximately 13.9 million receiving psychiatric treatment. Among these, around 6.4 million have not achieved remission following prior antidepressant therapy, and approximately 3.8 million have commercial insurance or federal healthcare coverage for NeuroStar Advanced Therapy. The estimated annual addressable market for treatment sessions in the U.S. is approximately $8.9 billion. Initial treatments typically involve antidepressant medications prescribed by primary care physicians, which have demonstrated limitations in effectiveness and side effects, as evidenced by the STAR*D Study.
Sources:
Neuronetics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Neuronetics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Neuronetics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
66.31 %